ATE526013T1 - Verfahren zur herbeiführung einer ovulation über einen nicht-polypeptid-camp-spiegel-modulator - Google Patents

Verfahren zur herbeiführung einer ovulation über einen nicht-polypeptid-camp-spiegel-modulator

Info

Publication number
ATE526013T1
ATE526013T1 AT07018904T AT07018904T ATE526013T1 AT E526013 T1 ATE526013 T1 AT E526013T1 AT 07018904 T AT07018904 T AT 07018904T AT 07018904 T AT07018904 T AT 07018904T AT E526013 T1 ATE526013 T1 AT E526013T1
Authority
AT
Austria
Prior art keywords
inducing ovulation
polypeptide camp
camp
mirror modulator
host
Prior art date
Application number
AT07018904T
Other languages
English (en)
Inventor
Stephen Palmer
Mark Tepper
Sean Mckenna
Michael C Macnamee
Aliza Eshkol
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Application granted granted Critical
Publication of ATE526013T1 publication Critical patent/ATE526013T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT07018904T 2001-12-14 2001-12-14 Verfahren zur herbeiführung einer ovulation über einen nicht-polypeptid-camp-spiegel-modulator ATE526013T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01274987A EP1463493B1 (de) 2001-12-14 2001-12-14 Verfahren zum herbeiführen eines eisprungs mittels eines nicht-polypeptid camp-level-modulators
PCT/EP2001/014730 WO2003051344A1 (en) 2001-12-14 2001-12-14 Methods of inducing ovulation_using a non-polypeptide camp level modulator

Publications (1)

Publication Number Publication Date
ATE526013T1 true ATE526013T1 (de) 2011-10-15

Family

ID=8164724

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01274987T ATE374606T1 (de) 2001-12-14 2001-12-14 Verfahren zum herbeiführen eines eisprungs mittels eines nicht-polypeptid camp-level- modulators
AT07018904T ATE526013T1 (de) 2001-12-14 2001-12-14 Verfahren zur herbeiführung einer ovulation über einen nicht-polypeptid-camp-spiegel-modulator

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01274987T ATE374606T1 (de) 2001-12-14 2001-12-14 Verfahren zum herbeiführen eines eisprungs mittels eines nicht-polypeptid camp-level- modulators

Country Status (18)

Country Link
US (1) US7507707B2 (de)
EP (2) EP1908463B1 (de)
JP (1) JP4532115B2 (de)
KR (2) KR20040075004A (de)
CN (1) CN1582146A (de)
AT (2) ATE374606T1 (de)
AU (1) AU2002217111B2 (de)
BR (2) BR0117198A (de)
CA (1) CA2469939C (de)
DE (1) DE60130813T2 (de)
DK (2) DK1463493T3 (de)
EA (1) EA011213B1 (de)
ES (1) ES2293965T3 (de)
IL (3) IL162506A0 (de)
MX (1) MXPA04005782A (de)
PT (2) PT1908463E (de)
UA (1) UA80418C2 (de)
WO (1) WO2003051344A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
WO2004087211A2 (en) 2003-04-01 2004-10-14 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
EP1708715A1 (de) * 2004-01-17 2006-10-11 Boehringer Ingelheim International GmbH Verwendung von substituierten pteridinen zur behandlung von atemwegserkrankungen
DE102004002557A1 (de) * 2004-01-17 2005-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
EP1915155A1 (de) * 2005-08-03 2008-04-30 Boehringer Ingelheim International GmbH Dihydropteridinone bei der behandlung von atemwegserkrankungen
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
EP2185559A1 (de) * 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Kristalline form eines dihydropteridionderivats
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
CN103169699B (zh) * 2011-12-22 2014-11-12 中国农业大学 来曲唑在用于制备成年牛超数排卵药物中的应用
WO2014089913A1 (zh) * 2012-12-12 2014-06-19 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的并环化合物
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087615A (en) 1989-03-17 1992-02-11 Applied Research Systems Ars Holding N.V. Novel method of ovulation induction in humans
GB9603723D0 (en) 1996-02-22 1996-04-24 Merck & Co Inc Diphenyl pyridyl derivatives as pde iv inhibitors
US5710170A (en) 1995-12-15 1998-01-20 Merck Frosst Canada, Inc. Tri-aryl ethane derivatives as PDE IV inhibitors
AP1147A (en) 1996-05-03 2003-02-25 Pfizer Substituted indazole derivatives and related compounds.
US5834485A (en) 1996-05-20 1998-11-10 Chiroscience Limited Quinoline sulfonamides and their therapeutic use
NZ332340A (en) 1996-05-20 2000-04-28 Darwin Discovery Ltd 4-(aryl or heteroaryl) substituted benzofurancarboxamide derivatives and medicaments
EP0952832B1 (de) 1996-05-20 2008-08-27 Darwin Discovery Limited Chinolincarboxamide als tnf-inhibitoren und als pde-iv inhibitoren
WO1997048697A1 (en) 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
ES2201299T3 (es) 1996-06-25 2004-03-16 Pfizer Inc. Derivados sustituidos de indazol y su uso como inhibidores de fosfodiesterasa (pde) de tipo iv y factor de necrosis tumoral (tnf)`.
GB9614718D0 (en) 1996-07-12 1996-09-04 Bayer Ag 3-ureido-pyridofurans and -pyridothiophenes
PL194673B1 (pl) 1996-10-02 2007-06-29 Janssen Pharmaceutica Nv Pochodna 2-cyjanoiminoimidazolu, sposób jej wytwarzania i zastosowanie oraz kompozycja farmaceutyczna
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
AU711587B2 (en) 1996-11-06 1999-10-14 Darwin Discovery Limited Quinolines and their therapeutic use
JP3237109B2 (ja) * 1996-12-13 2001-12-10 田辺製薬株式会社 医薬組成物
US6472425B1 (en) * 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
EP1082129B1 (de) * 1998-04-23 2003-10-29 Zentaris AG Methode zur behandlung von fruchtbarkeitsstörungen
WO1999061010A2 (en) * 1998-05-26 1999-12-02 Schering Aktiengesellschaft Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound
PT1086096E (pt) 1998-06-10 2003-12-31 Altana Pharma Ag Benzamidas com substituintes etra-hidrofuraniloxi como inibidores da fosfodiesterase 4
US6316472B1 (en) 1999-05-13 2001-11-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
HU229439B1 (hu) * 1999-08-21 2013-12-30 Takeda Gmbh Roflumilast és salmeterol szinergetikus kombinációja
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
JP2004500835A (ja) * 2000-04-17 2004-01-15 バイオイメージ　エイ／エス 生細胞でのホスホジエステラーゼ（ｐｄｅ）酵素の細胞内分布を調節する化合物の同定法
WO2001087287A2 (en) * 2000-05-19 2001-11-22 Applied Research Systems Ars Holding N.V. Use of pyrazole derivatives for treating infertility
WO2001093909A2 (en) * 2000-06-06 2001-12-13 Glaxo Group Limited Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor
US20020065324A1 (en) * 2000-08-11 2002-05-30 Stephen Palmer Methods of inducing ovulation
US6953774B2 (en) * 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
WO2004087211A2 (en) * 2003-04-01 2004-10-14 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility

Also Published As

Publication number Publication date
DK1908463T3 (da) 2011-11-28
IL162506A (en) 2012-03-29
DE60130813D1 (de) 2007-11-15
MXPA04005782A (es) 2004-09-13
KR20040075004A (ko) 2004-08-26
DK1463493T3 (da) 2008-02-04
CA2469939A1 (en) 2003-06-26
KR101056916B1 (ko) 2011-08-12
IL205106A0 (en) 2010-11-30
AU2002217111B8 (en) 2003-06-30
PT1908463E (pt) 2011-12-19
ES2293965T3 (es) 2008-04-01
AU2002217111A1 (en) 2003-06-30
EP1908463A3 (de) 2009-11-25
EA200400808A1 (ru) 2004-12-30
PT1463493E (pt) 2008-01-04
KR20090009336A (ko) 2009-01-22
IL162506A0 (en) 2005-11-20
BR0117198A (pt) 2004-10-26
AU2002217111B2 (en) 2007-05-31
ATE374606T1 (de) 2007-10-15
EA011213B1 (ru) 2009-02-27
EP1463493B1 (de) 2007-10-03
IL205106A (en) 2013-02-28
DE60130813T2 (de) 2008-07-03
EP1908463A2 (de) 2008-04-09
CA2469939C (en) 2012-06-19
EP1908463B1 (de) 2011-09-28
US7507707B2 (en) 2009-03-24
JP2005516924A (ja) 2005-06-09
US20050148501A1 (en) 2005-07-07
WO2003051344A1 (en) 2003-06-26
UA80418C2 (en) 2007-09-25
BRPI0117198B1 (pt) 2018-03-13
EP1463493A1 (de) 2004-10-06
CN1582146A (zh) 2005-02-16
JP4532115B2 (ja) 2010-08-25

Similar Documents

Publication Publication Date Title
ATE526013T1 (de) Verfahren zur herbeiführung einer ovulation über einen nicht-polypeptid-camp-spiegel-modulator
HUP0004211A2 (hu) PDE-5 inhibitorok alkalmazása tüdõ magas vérnyomás kezelésére szolgáló gyógyszerkészítmények elõállítására
ATE475883T1 (de) Verfahren zur messung der wirkstärke von glatirameracetat
CY1110259T1 (el) Ανοσορυθμιστης
WO2002102314A3 (en) Purine inhibitors of phosphodiesterase (pde) 7
NO2010020I1 (no) 5-{{4-[(2,3-dimetyl-2H-indazot-6-yl)(metyl)amino]pyrimidin-2-yl}amino)-2-metylbenzensulfonamid Pazopanib.
DE60110937D1 (de) Nicht isothermisches verfahren zum herstellen von hohlen verbundteilen
ATE245648T1 (de) 1h-pyrazolo(3,4-d)pyrimidine-4,6-dione als inhibitoren für die vermehrung von t-zellen
ATE372334T1 (de) Phenylpyrazolderivate als seh-inhibitoren
SE9702483D0 (sv) New compound
WO2001062979A3 (en) Dentification of partial agonists of the a2a adenosine receptor
CA2046755A1 (en) /2r/-2-[di/2-propyl/phosphonylmethoxy]-3-p-toluenesulfonyloxy-1-trimethylacetoxypropane, its preparation and use
DE60017088D1 (de) System und verfahren zur überprüfung von fingerabdrücken
GB0000561D0 (en) Treatment of diabetic ulcers
EE05384B1 (et) LaiaspektrilisedÁ2-(asendatudÁamino)bensoksasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁkasutamine,ÁfarmatseutilineÁkompositsioonÁjaÁmeetodÁretroviiruseÁreplikatsiooniÁinhibeerimiseks
DE60137862D1 (de) Verfahren zur rückgewinnung von hexamethylendiamin (hmd) mit geringem polarographischen reduzierbaren verunreinigungen (prv) aus gemischen enthaltend hmd, aminocapronitril und prv
ATE321748T1 (de) Verfahren zur fluormethylierung von alkoholen
DE60233936D1 (de) Therapeutische Zusammenseztungen zur Toleranzinduktion
DE50112690D1 (de) Verfahren zur aufbereitung von pyrrolidon- und n-vinylpyrrolidon-rückständen
DE60031315D1 (de) Verfahren zur Herstellung von Derivaten von i(1,5-Diaryl)pyrazol-3-ylöpropansäure
PT1335730E (pt) Tratamento da ejaculacao prematura
WO2002003993A3 (en) Use of inhibitors to multidrug resistance protein 5 (mrp5) to enhance intracellular levels of cyclic nucleotides
SE0202608D0 (sv) New sequences
WO2004098374A3 (en) System and method for enhanced medicament-based treatment of disease
IT1318634B1 (it) Processo per la preparazione dell'acido 1-metil-5-(4-metilbenzoil)-pirrol-2-acetilamminoacetico.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1908463

Country of ref document: EP